ArticleFrontiers in genetics2025
Prediction of NR3C1 as a methylation marker for the prevention and treatment of gastric cancer in Rhizoma Atractylodis Macrocephalae based on machine learning algorithm and bioinformatics analysis.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to identify the markers of Rhizoma Atractylodis Macrocephalae (RAM) for the prevention and treatment of gastric cancer using bioinformatics analysis. Methods: The main active components of RAM were screened using the Traditional Chinese Medicine Systematic Pharmacology Profiling Platform (TCMSP) and SwissADME, the target genes of RAM were screened using WGCNA and three machine learning algorithms, and the target genes were analyzed clinically and by methylation. Results: Three core genes, namely, CA2, HSP90AA1, and NR3C1, were screened by WGCNA and three machine learning algorithms. Clinical correlation analysis and epigenetic analyses showed that these genes play the most important role in gastric cancer. In gastric cancer, there was a strong correlation between NR3C1 methylation and its mRNA expression, suggesting that methylation of NR3C1 may be involved in the regulation of its expression. Therefore, methylation correlation analysis of NR3C1 was performed, and it was found that the methylation type of NR3C1 was mainly m6A methylation; the frequency of methylation hypermutation in the CDS region was also high, and the homologous region and the promoter of the NR3C1 gene showed hypomethylation and hypermethylation differences in the analyses of gastric tissues, races, and gastric cancer subtypes, respectively. Among the methylated peninsular mutations, the TSS200; 5'UTR, 5'UTR, and TSS1500; 5'UTR regions were statistically significant. Conclusion: NR3C1 can be used as a potential methylation marker of RAM for the prevention and treatment of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.